Halozyme Therapeutics, Inc. (HALO) Financial Statements
Halozyme Therapeutics, Inc. (HALO) reported trailing twelve-month revenue of $1.7B (up 41.2% year on year) and net income of $413.6M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: $806.2M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
HALOHalozyme Therapeutics, Inc.Follow HALO — free
—
Price chart with a free account
- Market cap
- 14.3B
- P/E TTM
- 36.6
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 5 Nov, in 12 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2011 Dec 11 | FY2012 Dec 12 | FY2013 Dec 13 | FY2014 Dec 14 | FY2015 Dec 15 | FY2016 Dec 16 | FY2017 Dec 17 | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.06 | 0.04 | 0.05 | 0.08 | 0.14 | 0.15 | 0.32 | 0.15 | 0.20 | 0.27 | 0.44 | 0.66 | 0.83 | 1.02 | 1.40 | 1.66 | |
| Gross profit | 0.06 | 0.04 | 0.05 | 0.05 | 0.11 | 0.11 | 0.29 | 0.14 | 0.15 | 0.22 | 0.36 | 0.52 | 0.64 | 0.86 | 1.17 | 1.37 | |
| Research & development | 0.06 | 0.07 | 0.10 | 0.08 | 0.09 | 0.15 | 0.15 | 0.15 | 0.14 | 0.03 | 0.04 | 0.07 | 0.08 | 0.08 | 0.08 | 0.10 | |
| Operating income | -0.02 | -0.05 | -0.08 | -0.06 | -0.03 | -0.08 | 0.08 | -0.07 | -0.07 | 0.14 | 0.28 | 0.27 | 0.34 | 0.55 | 0.47 | 0.60 | |
| Pre-tax income | — | — | — | -0.07 | -0.03 | -0.10 | 0.06 | -0.08 | -0.07 | 0.13 | 0.25 | 0.25 | 0.35 | 0.56 | 0.47 | 0.58 | |
| Income tax | — | — | — | — | — | 0.00 | -0.00 | 0.00 | -0.00 | 0.00 | -0.15 | 0.05 | 0.07 | 0.11 | 0.15 | 0.17 | |
| Net income | -0.02 | -0.05 | -0.08 | -0.07 | -0.03 | -0.10 | 0.06 | -0.08 | -0.07 | 0.13 | 0.40 | 0.20 | 0.28 | 0.44 | 0.32 | 0.41 | |
| Diluted EPS ($) | -0.19 | -0.48 | -0.74 | -0.56 | -0.25 | -0.81 | 0.45 | -0.56 | -0.50 | 0.91 | 2.74 | 1.44 | 2.10 | 3.43 | 2.56 | 3.43 | |
| Diluted shares (bn) | — | — | — | — | — | — | 0.139 | 0.144 | 0.144 | 0.141 | 0.147 | 0.141 | 0.134 | 0.129 | 0.124 | — |
USD billions · SEC XBRL
Halozyme Therapeutics, Inc. — questions
- What is Halozyme Therapeutics, Inc.'s revenue?
- $1.7B over the twelve months to 2026-06-30, up 41.2% year on year, from its 10-Q and 10-K filings.
- What is Halozyme Therapeutics, Inc.'s net income?
- $413.6M over the twelve months to 2026-06-30.
- What is Halozyme Therapeutics, Inc.'s free cash flow?
- $806.2M over the twelve months to 2026-06-30.
- What are Halozyme Therapeutics, Inc.'s diluted earnings per share?
- $3.43 over the twelve months to 2026-06-30.
Every figure on this page comes from Halozyme Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.